https://scholars.lib.ntu.edu.tw/handle/123456789/582080
標題: | Treatment of chronic hepatitis B in Asia-Pacific countries: Is the Asia-Pacific consensus statement being followed? | 作者: | Sung J.J.Y. Amarapurkar D. Chan H.L.Y. Cheng J. JIA-HORNG KAO Han K.-H. Piratvisuth T. |
公開日期: | 2010 | 卷: | 15 | 期: | 4 | 起(迄)頁: | 607-616 | 來源出版物: | Antiviral Therapy | 摘要: | Background: The Asia-Pacific consensus guidelines for the management of chronic hepatitis B state that the principal indicators for starting therapy are increased HBV DNA levels (?20,000 IU/ml for hepatitis B e antigen [HBeAg]-positive status and >2,000 IU/ml for HBeAg-negative status) and alanine aminotransferase (ALT) levels >2x the upper limit of normal. We aimed to determine whether clinicians in the Asia-Pacific region are treating patients with chronic hepatitis B according to the Asia-Pacific consensus statement on the management of chronic hepatitis B. Methods: An online survey of chronic hepatitis B treatment practices was prepared, consisting of 14 questions grouped into seven categories: patient statistics, treatment statistics, treatment decision, first-choice treatment, treatment duration, future directions and patient preference. Results: In total, 124 respondents from 12 countries completed the survey. Most respondents indicated that detectable HBV DNA was either the first or second most important factor when deciding whether to initiate therapy. Many physicians were unsure about initiation of treatment in patients >40 years of age when ALT levels were within the normal range. Oral antiviral drugs were the most frequently used medication because of their effectiveness, safety and ability to provide sustained viral suppression. Conversely, the most important reasons for selecting interferon therapy were effectiveness, fixed duration of treatment and lack of drug resistance. Criteria for stopping treatment generally followed the recommendations included in the guidelines. Conclusions: These data suggest that clinicians from the Asia-Pacific region use criteria beyond those advocated in treatment guidelines when deciding whether to initiate treatment in HBV-infected patients. ?2010 International Medical Press. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77956862692&doi=10.3851%2fIMP1561&partnerID=40&md5=cdcd19fe23116b0c59b41840277359d8 https://scholars.lib.ntu.edu.tw/handle/123456789/582080 |
ISSN: | 1359-6535 | DOI: | 10.3851/IMP1561 | SDG/關鍵字: | alanine aminotransferase; alpha interferon; antivirus agent; hepatitis B(e) antigen; interferon; peginterferon; virus DNA; alanine aminotransferase; antivirus agent; hepatitis B(e) antigen; antiviral resistance; article; Asia; chronic hepatitis; drug efficacy; drug safety; health survey; Hepatitis B virus; human; medical decision making; physician; practice guideline; priority journal; treatment duration; Australia; blood; clinical practice; drug administration; drug effects; gastroenterology; genetics; Hepatitis B, Chronic; immunology; Internet; questionnaire; standards; virology; Alanine Transaminase; Antiviral Agents; Asia; Australia; DNA, Viral; Drug Administration Schedule; Gastroenterology; Guideline Adherence; Guidelines as Topic; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Internet; Physician's Practice Patterns; Questionnaires; Alanine Transaminase; Antiviral Agents; Asia; Australia; DNA, Viral; Drug Administration Schedule; Gastroenterology; Guideline Adherence; Guidelines as Topic; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Internet; Physician's Practice Patterns; Questionnaires |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。